Protalix BioTherapeutics (PLX) Stock Price, Quote, News & History | Benzinga

SPY778.45+0.04%QQQ744.10−0.26%BTC/USD83,413.59+2.05%DIA516.25−0.32%GLD381.47−0.18%TLT78.37+0.41%

Protalix BioTherapeutics Inc (PLX) Stock Price, Quote, News & History

PLXAMEX

Trade with Public

Trade with Public

$2.75

-0.03-1.08%

Last update: Oct 13, 5:32 PM

$2.84

0.062.16%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.79

Close

$2.75

Volume / Avg.

966.79K / 746.91K

Day Range

$2.84 - $2.84

52 Wk Range

1.60 - 3.19

Market Cap

$223.99M

P/E Ratio

12.09

Dividend Yield

-

Exchange

AMEX

RSI

61

Short Interest

3.93%

Days to Cover

4.29

Recent Protalix BioTherapeutics, Inc. News

Why Is Protalix BioTherapeutics Stock Falling On Friday?

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.

Vandana Singh

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

Vandana Singh

Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult

Vandana Singh

Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil

Nabaparna Bhattacharya

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

9.92M

Investing Cash Flow (TTM)

-1.03M

Financing Cash Flow (TTM)

296.00K

Free Cash Flow (TTM)

7.67M

Capital Expenditure (TTM)

-2.26M

Net Change in Cash (TTM)

9.19M

Analyst Trends and Forecast

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$192.54M

PE Ratio (TTM)

12.09

PE Ratio (FWD)

55.56

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.80

PB Ratio (TTM)

3.14

Earnings Yield % (TTM)

8.27%

Earnings Yield % (FWD)

1.80%

EV / EBITDA (TTM)

7.33

Price / EBITDA (TTM)

8.59

Price / Free Cash Flow (TTM)

29.41

Book Value / Share

$0.89

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$27.42M

Debt to Equity

0.13

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-